ALNY - Company ID 0001178670
ALNYLAM PHARMACEUTICALS, INC. trades as ALNY and has a market capitalization of $41.48 B, making it the #376 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $3.71B, up 65.2% from the prior year and net income of $313.75M. This page tracks ALNYLAM PHARMACEUTICALS, INC. through 1,651 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years ALNYLAM PHARMACEUTICALS, INC.'s revenue grew from $47.16M to $3.71B, a compound annual growth rate of 62.4%. Net profit margin expanded from -869.6% to 8.4% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-14 |
| SCHEDULE 13G/A | - | 2026-05-14 |
| Insider trade | 4 | 2026-05-14 |
| SCHEDULE 13G/A | - | 2026-05-06 |
| Quarterly report | 10-Q | 2026-04-30 |
| Major company event | 8-K | 2026-04-30 |
| SCHEDULE 13G | - | 2026-04-29 |
| Insider trade | 4 | 2026-04-07 |
The largest companies sharing ALNYLAM PHARMACEUTICALS, INC.'s SEC industry classification (pharmaceutical preparations).
ALNYLAM PHARMACEUTICALS, INC. (ALNY) has a market capitalization of $41.48 B as of 2026-07-09, ranking #376 among US-listed companies.
ALNYLAM PHARMACEUTICALS, INC. reported revenue of $3.71B for fiscal year 2025, an increase of 65.2% year over year.
Yes. ALNYLAM PHARMACEUTICALS, INC. reported net income of $313.75M in its latest fiscal year.